CD Genomics provides accurate Circulating Tumor DNA Sequencing services using next-generation sequencing (NGS) technology.
Cell-free, circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies. Today, researchers are investigating the use of ctDNA as a biomarker for detecting the presence of tumors in various cancer types. In the future, ctDNA could potentially serve as a noninvasive approach for real-time monitoring of treatment response and identifying candidates for therapy.
Next-generation sequencing (NGS) offers the sensitivity and specificity needed to detect low levels of ctDNA in the bloodstream. In addition to targeting a single gene or a subset of genes, NGS can also identify genome-wide tumor-derived alterations in ctDNA. More information, please visit the website: http://www.cd-genomics.com/Circulating-Tumor-DNA-Sequencing.html